343247-69-8 Usage
Description
1-(4-Chloro-3-(trifluoromethyl)phenyl)urea is an organic compound that is identified as an impurity in Sorafenib (S676850), a medication used as a multiple kinase inhibitor. It is characterized by its molecular structure, which includes a urea group attached to a substituted phenyl ring with a chlorine atom at the 4th position and a trifluoromethyl group at the 3rd position.
Uses
Used in Pharmaceutical Industry:
1-(4-Chloro-3-(trifluoromethyl)phenyl)urea is used as an impurity in the production of Sorafenib, a multiple kinase inhibitor. It is significant in the pharmaceutical industry due to its association with Sorafenib, which targets both RAF and receptor tyrosine kinases that promote angiogenesis. This makes it an important compound in the development and production of antineoplastic drugs, which are used to treat various types of cancer.
As an impurity in Sorafenib, 1-(4-Chloro-3-(trifluoromethyl)phenyl)urea may also play a role in the overall effectiveness and safety profile of the drug. It is crucial to monitor and control the levels of this impurity to ensure the quality, efficacy, and safety of Sorafenib as a therapeutic agent.
Check Digit Verification of cas no
The CAS Registry Mumber 343247-69-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,3,2,4 and 7 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 343247-69:
(8*3)+(7*4)+(6*3)+(5*2)+(4*4)+(3*7)+(2*6)+(1*9)=138
138 % 10 = 8
So 343247-69-8 is a valid CAS Registry Number.
343247-69-8Relevant articles and documents
Preparation method of sorafenib compound
-
Paragraph 0015; 0028-0036, (2018/09/08)
The invention discloses a preparation method of a sorafenib compound. The preparation method comprises the following steps of: adopting reaction of 2-chloro-5-aminotrifluorotoluene and sodium cyanateto prepare a compound III, reaction of 4-bromophenol (compound IV) and a compound V to prepare a compound VI, and reaction of the compound VI and the compound III to obtain a final product, i.e., sorafenib (I). The preparation method disclosed by the invention has the beneficial effects that raw materials for reaction are low in cost and easy in obtaining, the process route is simple, the total yield is high, the side products are fewer, so that the preparation method is suitable for industrial production.
Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process
-
Page/Page column 21, (2010/12/29)
There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A) wherein R′ is selected from the group consisting of hydrogen, —C(O)OA, —C(O)CX3, —C(O)NH2, —C(O)—NHOH or There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-ureidophenoxy)picolinamide, 4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenylcarbamate derivative and N-methyl-4-(4-(2,2,2-trihaloacetamido)phenoxy)picolinamide, processes for their preparation and their use in the preparation of sorafenib.
